One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The two eviQ protocols treat severe kidney impairment differently: the Ewing regimen directs an alternative where the fractionated lymphoma regimen permits a reduction or alternative. The label itself supplies qualitative renal precautions, not these numeric bands.
What to reconcile: Match the malignancy, full chemotherapy protocol, intent, renal measurement and KRT. Different protocols from the same organization are not independent validation or interchangeable prescriptions.
Open this note and its source referencesProtocol-based baseline modifications coexist with the label warning about glomerular and tubular injury, including delayed effects. A baseline reduction is not proof that treatment-emergent injury is controlled.
What to reconcile: Review renal trends and tubular/electrolyte findings throughout and after treatment; consider the complete toxicity management instructions rather than continuing from a baseline table alone.
Open this note and its source referencesFor this lymphoma protocol, use full-dose ifosfamide at eGFR at least 60 and 45-59, with increased adverse-event risk at 45-59. At both 30-44 and 15-29, reduce by 20% or use an alternative protocol, accounting for increased adverse-event risk. Below 15 without KRT, obtain multidisciplinary guidance; KRT also requires specialist collaboration. These are modifiers of the specified regimen, not stand-alone doses or permission to override another protocol.
RDM43-professional-ifosfamide-ifex-79531527a2-C1 · Source locator: Dose modifications: Kidney dosing recommendations, ifosfamide column and preceding notes.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ifosfamide-ifex&s1=RDM43-professional-ifosfamide-ifex-79531527a2&h1=229c3309a0d5bffec38679a0c092e448a5406ef01e2c567513bcf45f5cc7e9cd